Table 3 Results of multiple logistic- regression analysis of PIMs-related risk factors that can affect hospitalization
Number of patients | Adjusted† OR (95% CI) | p value | |
|---|---|---|---|
hospitalized/Total (%) | |||
Age | 0.99 (0.98–0.99) | .001** | |
Sex | |||
Male | 1113/5653 (19.7) | 1.56 (1.40–1.72) | < .001*** |
Female | 787/5588 (14.1) | ||
Total number of drugs | 1.06 (1.03–1.08) | < .001*** | |
Number of medical departments | 1.43 (1.29–1.59) | < .001*** | |
Benzodiazepine derivatives | 142/770 (18.4) | 0.90 (0.74–1.10) | 0.314 |
Non-benzodiazepine hypnotics | 78/380 (20.5) | 1.11 (0.85–1.45) | 0.439 |
Tricyclic antidepressants | 9/45 (20.0) | 1.09 (0.51–2.35) | 0.821 |
Sulpiride | 2/24 (8.3) | 0.36 (0.81–1.58) | 0.173 |
Antiparkinsonian drugs | 4/35 (11.4) | 0.64 (0.22–1.84) | 0.409 |
(anticholinergic drugs) | |||
Combined therapy with multiple antithrombotic drugs | 80/270 (29.7) | 1.26 (0.94–1.69) | 0.116 |
(antiplatelet drugs, anticoagulants) | |||
Digoxin (> 0.125 mg/day) | 1/6 (16.7) | 0.27 (0.30–2.48) | 0.249 |
Loop diuretics | 198/596 (33.2) | 1.73 (1.38–2.16) | < .001*** |
Alderostone antagonists | 123/409 (30.1) | 1.24 (0.95–1.61) | 0.108 |
α1-Receptor blockers | 20/105 (19.0) | 0.74 (0.44–1.24) | 0.25 |
nonselective for receptor subtypes | |||
H1 receptor antagonists | 11/49 (22.4) | 0.98 (0.49–1.98) | 0.965 |
(first generation) | |||
H2 receptor antagonists | 107/647 (16.5) | 0.80 (0.64–0.99) | .044* |
Antiemetic drugs | 34/126 (27.0) | 1.45 (0.96–2.19) | 0.079 |
Sulfonylureas | 27/173 (15.6) | 0.71 (0.45–1.12) | 0.14 |
Biguanides | 49/291 (16.8) | 0.82 (0.58–1.17) | 0.274 |
Thiazolidine derivatives | 10/89 (11.2) | 0.53 (0.27–1.08) | 0.079 |
α-Glucosidase inhibitors | 45/212 (21.2) | 1.04 (0.72–1.50) | 0.847 |
SGLT2 inhibitors | 4/40 (10.0) | 0.48 (0.17–1.42) | 0.185 |
Muscarinic receptor antagonists | 18/139 (12.9) | 0.58 (0.35–0.96) | 0.036 |
Oxybutynin (oral) | 0/3 (0) | NA | |
NSAIDs | 197/836 (23.5) | 1.29 (1.08–1.54) | .006** |